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ABSTRACT
Objective: This study aimed to identify the oncogenes at
20q involved in colorectal adenoma to carcinoma
progression by measuring the effect of 20q gain on mRNA
expression of genes in this amplicon.
Methods: Segmentation of DNA copy number changes
on 20q was performed by array CGH (comparative
genomic hybridisation) in 34 non-progressed colorectal
adenomas, 41 progressed adenomas (ie, adenomas that
present a focus of cancer) and 33 adenocarcinomas.
Moreover, a robust analysis of altered expression of
genes in these segments was performed by microarray
analysis in 37 adenomas and 31 adenocarcinomas.
Protein expression was evaluated by immunohistochem-
istry on tissue microarrays.
Results: The genes C20orf24, AURKA, RNPC1, TH1L,
ADRM1, C20orf20 and TCFL5, mapping at 20q, were
significantly overexpressed in carcinomas compared with
adenomas as a consequence of copy number gain of 20q.
Conclusion: This approach revealed C20orf24, AURKA,
RNPC1, TH1L, ADRM1, C20orf20 and TCFL5 genes to be
important in chromosomal instability-related adenoma to
carcinoma progression. These genes therefore may serve
as highly specific biomarkers for colorectal cancer with
potential clinical applications.
The majority of cancers are epithelial in origin and
arise through a stepwise progression from normal
cells, through dysplasia, into malignant cells that
invade surrounding tissues and have metastatic
potential. The colorectal adenoma to carcinoma
progression is a classic example of this process.1 2
Genomic instability is a crucial step in this
progression and occurs in two ways in colorectal
cancer (CRC).3 DNA mismatch repair deficiency
leading to microsatellite instability (MIN) explains
about 15% of cases.4–6 In the other 85%, genomic
instability occurs at the chromosomal level (CIN)
giving rise to aneuploidy. While for a long time
chromosomal aberrations have been regarded as
random noise, it is now well established that these
DNA copy number changes occur in specific
patterns and are associated with different clinical
behaviour.7–9 Nevertheless, neither the cause of
CIN in human cancer progression nor its biological
consequences have been fully appreciated.
Chromosomal aberrations frequently reported in
CRC are 7pq, 8q, 13q and 20q gains, and 4pq, 5q,
8p, 15q, 17p and 18q losses.10–13 Of these, especially
8q, 13q and 20q gains and 8p, 15q, 17p and 18q
losses are associated with colorectal adenoma to
carcinoma progression.
Gain of 20q is observed in .65% of CRCs.14
Gains of 20q are also common in other tumour
types and have been associated with poor outcome
in gastric cancer and CRC.15–20 The 20q13 amplicon
has been studied in detail in breast and gastric
cancers with restricted contig array comparative
genomic hybridisation (CGH), pinpointing several
genes as targets of amplification.21 22 Analysis of
DNA copy number changes at the gene level by
multiplex ligation-dependent probe amplification
showed that in CRC, besides 20q13, 20q11 is also
frequently amplified.23
This study aims to investigate dosage effects of
putative 20q oncogenes in colorectal adenoma to
carcinoma progression.
MATERIALS AND METHODS
Tumour samples
Forty-one formalin-fixed and paraffin-embedded
progressed adenomas (with a focus of carcinoma
present, also referred to as malignant polyps)
collected from the tissue archive of the department
of pathology at the VU University Medical Center
(VUmc), Amsterdam, The Netherlands, and 73
prospectively collected snap-frozen colorectal
tumour samples (37 non-progressed adenomas
and 36 carcinomas) were investigated. All samples
were used in compliance with the institution’s
ethical regulations.
The 41 progressed adenomas corresponded to 19
females and 18 males (three patients presented
more than one lesion). Mean age was 67 years
(range 45–86). From these, adenoma and carci-
noma components were analysed separately, add-
ing up to a total of 82 archival samples (4162).
The 73 frozen specimens corresponded to 31
females and 34 males (six patients had multiple
tumours). Mean age was 69 years (range 47–89).
All histological sections were evaluated by a
pathologist (G.A.M.).
Array CGH was performed on both sets of
samples, while expression microarrays were per-
formed on the frozen samples only.
DNA and RNA isolation
DNA from paraffin-embedded samples was
obtained as described previously.24 RNA and DNA
from snap-frozen tissues were isolated using
TRIzol (Invitrogen, Breda, The Netherlands)
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following the supplier’s instructions with some modifications,
described at http://www.english.vumc.nl/afdelingen/microar-
rays. Isolated RNA was subjected to purification using an
RNeasy Mini Kit (Qiagen, Venlo, The Netherlands). RNA and
DNA concentrations and purities were measured on a
Nanodrop ND-1000 spectrophotometer (Isogen, IJsselstein,
The Netherlands), and integrity was evaluated on a 1% agarose
ethidium bromide-stained gel.
Array CGH
A BAC/PAC (bacterial artificial chromosome/phage artificial
chromosome) array platform was used as described elsewhere.25
Arrays were scanned (Agilent DNA Microarray scanner G2505B,
Agilent Technologies, Palo Alto, California, USA) and Imagene
5.6 software (Biodiscovery, Marina del Rey, California, USA)
was used for automatic feature extraction with default settings.
Local background was subtracted from the signal median
intensities of both test and reference DNA. The median of the
triplicate spots was calculated for each BAC clone, and log2
ratios (tumour/normal) were normalised by subtraction of the
mode value of BAC clones on chromosomes 1–22 (UCSC July
2003 freeze of the Human Golden Path-NCBI Build 34). Clones
with standard deviation of the intensity of the three spots . 0.2
and with .20% missing values were excluded.
Expression microarrays
The Human Release 2.0 oligonucleotide library, containing
60mer oligonucleotides representing 28 830 unique genes,
designed by Compugen (San Jose, California, USA) was
obtained from Sigma-Genosys (Zwijndrecht, The
Netherlands). Printing of slides was done as described else-
where.26 Tumour RNA (30 mg) was hybridised against Universal
Human reference (Stratagene, Amsterdam, The Netherlands).
cDNA labelling and hybridisation procedures are described
elsewhere.26 Scanning of arrays and feature extraction were
performed as described above. Overall quality of experiments
was judged on microarray plots of intensities of raw data.
Normalisation was done either with TIGR Midas (http://www.
tm4.org/midas.html), using ‘‘Lowess’’ correction27 or with
‘‘Median’’ normalisation and implemented in the maNorm
function (Marray R bioconductor package), with identical
results. Interarray normalisation was also performed. Low
intensity values were replaced by the intensity value of 50.
Genes with .20% missing values were excluded.
Array CGH and expression microarray data sets are available
at Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.
gov/geo/,28 accession number GSE8067.
Microarray data analysis
Below, the steps of data analysis are discussed for array CGH
data, expression data and integrative analysis. To account for
multiple testing, either a false discovery rate (FDR) correction
was applied to the p values, or a very stringent p value cut-off
was used.
Array CGH data
To segment DNA copy number alterations, a smoothing
algorithm, ‘‘aCGH-Smooth’’, was applied.29 Smoothed log2
ratios of 20.15 and 0.15 were used as thresholds to define
gains and losses (99% CIs) obtained for 15 normal-to-normal
hybridisations. Only gains and losses covering at least three
consecutive BAC clones were included. Amplifications were
called when log2 ratios exceeded 1.0. DNA copy number data
were stored in ArrayCGHbase30 (http://arraydb.vumc.nl/
arrayCGHbase). Median absolute deviation (MAD) was deter-
mined for each case as a quality control. Cases with MAD >0.2
were excluded. Array CGH profiles were visualised in
ArrayCGHbase.
Supervised analysis, comparing two groups, was done using
CGHMultiArray.31 For analysis of paired samples (adenoma and
carcinoma components within progressed adenomas), an
adapted version of CGHMultiArray was used, based on the
Wilcoxon sign-rank test corrected for ties. Reported p values are
adjusted for multiple testing (FDR), unless stated otherwise.
For defining the most frequent smallest regions of overlap
(SRO) for gains on 20q, in all cases, STAC (significance testing
for aberrant copy number) was used.32
Microarray expression data
As all hybridisations were performed against a common
reference, all comparisons were relative between colorectal
adenomas and carcinomas.
Supervised analysis for comparing carcinomas and adenomas
was done using the Wilcoxon signed rank test, and a modified
version of this test—the total Thas score (http://www.cvstat.
ugent.be/index.php?page = techrep/techrep.htm) that is power-
ful when the distributions of the expression levels of both
groups do not differ over the whole range of expression levels.
This occurs when not all cases in the carcinoma and adenoma
groups have differentially expressed genes, but differences rather
appear in subpopulations. Genes were considered as differen-
tially expressed when a Wilcoxon test p value was ,1e-5 and a
Thas p value was ,0.05, corresponding to an FDR of ,0.05.
To disclose genes whose expression is influenced by 20q gain,
tumours with and without 20q gain were compared. Gene
expression was regressed on copy number count using a linear
model.
To evaluate the discriminatory power of candidate genes for
classifying adenomas versus carcinomas, a stepwise linear
discriminant analysis with leave one out cross-validation was
performed on mRNA expression data (SPSS 15.0 for Windows,
SPSS, Chicago, Illinois, USA).
Integration of copy number and expression data
ACE-it (Array CGH Expression integration tool) was applied to
test whether gene dosage affects RNA expression.33 Only genes
on chromosome 20 are presented. We used a cut-off value of
0.15 for gains and losses, a default group value of 9 and an FDR
(0.10.
Quantitative reverse transcription-PCR (qRT-PCR)
RNA (1 mg) was treated with DNase I and reverse transcribed to
cDNA using oligo(dT)20 primer with Superscript II reverse
transcriptase (Invitrogen).
qRT-PCR was performed in duplicate on 15 adenomas and 15
carcinomas for six candidate genes. A master mix was prepared
with 12.5 ml of SYBR Green PCR master mix (Applied
Biosystems, Nieuwerkerk a/d IJssel, The Netherlands), 0.5 mM
of each primer in 22.5 ml. cDNA (25 ng in 2.5 ml) was added to
the mix. Reactions were performed in a 7300 Real-time PCR
System (Applied Biosystems). Amplification conditions com-
prised a denaturation step at 95uC for 10 min and 50 cycles at
95uC for 15 s and annealing temperature for 1 min
(Supplementary table 1). Relative expression levels were
determined following the 2DDCt method,34 using the b-2-
microglobulin gene as a reference. This gene was previously
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demonstrated not to differ in expression between adenomas and
carcinomas.35
Immunohistochemistry on tissue microarrays (TMAs)
A TMA was constructed with 57 tumours (32 adenomas and 25
carcinomas) for which array CGH and/or expression microarray
data were available. For each tumour, three cores from different
locations within the tumour were included in the array. A 4 mm
section of the array was used for immunohistochemistry. After
deparaffination in xylene, and rehydration through graded
alcohol to water, endogenous peroxidase was blocked with
hydrogen peroxide (0.3% H2O2/methanol) for 25 min. Antigen
retrieval was done by autoclaving in citrate buffer (10 mM; pH
6.0). Primary Aurora A monoclonal antibody NCL-L-AK2 from
Novocastra Laboratories (Newcastle, UK) was incubated over-
night at 4uC at a dilution of 1:50. The secondary mouse
antibody, K4006, from the Envision kit (DAKO, Heverlee,
Belgium) was incubated for 30 min at room temperature.
Counterstaining was done with Mayer’s haematoxylin.
Incubation without primary antibody was used as negative
control. The colorectal cancer cell line Caco-2, which has a 20q
gain and is known to express Aurora A, was used as positive
control. Caco-2 cells were fixed and paraffin embedded, and
sections were taken along in the same run of immunohisto-
chemistry as that in which the TMA was processed. Caco-2
produced strong nuclear, mostly along with cytoplasmic,
staining in .75% of tumour cells, and this pattern was taken
as reference for intense staining. Next, the spectrum of staining
in the respective cores on the TMA was surveyed in terms of
intensity and positive nuclei. Only staining in tumour cells (ie,
either adenoma or carcinoma cells) was considered. Cores of the
TMA typically contained 4–17 crypts with every crypt .100
cells, which all were evaluated. Basically, three staining patterns
were seen: no staining at all, strong staining comparable with
that observed in Caco-2 cells; and an intermediate pattern that
showed positive staining, but clearly less intense than in Caco-2
cells. The intensity of staining was taken as the most important
parameter. In pattern 2, typically 50% to .75% of nuclei
showed intense staining, while in pattern 1 typically 25% to
.75% of nuclei showed weak staining. For score 0, no more
than a scattered weakly positive cell was tolerated. Based on
evaluation of up to three cores by two independent observers, a
score ranging from 0 to 2 was assigned per tumour, with score 0
corresponding to no signal, score 2 corresponding to the strong
signal that was observed in the positive control Caco-2, and
score 1 for an intermediate intensity staining. In the case of
disagreement between observers, a third observer was consulted
and the majority score was noted.
Cochran–Armitage test analysis was performed to compare
protein expression with lesion type (adenoma, carcinoma). The
Jonckheere–Terpstra test was performed to compare protein
expression with log2 ratios (microarray expression data). Both
tests make explicit use of the ordinality of the protein levels
of expression. Differences were considered significant when
p ,0.05.
RESULTS
Delimiting gained regions on 20q
We analysed by array CGH 41 progressed adenomas, which
were previously studied by classical CGH. We analysed the
adenoma and carcinoma components of these samples sepa-
rately. Gain of 20q occurred in .60% of the cases (fig 1A,B;
Supplementary fig 1A). The pattern of copy number changes
did not differ between adenoma and carcinoma components (as
determined by CGHMultiArray), although it sometimes
showed lower amplitudes in the adenoma component (fig 1A,B).
Next, we analysed the DNA copy number status of 37 non-
progressed adenomas and 36 carcinomas. From these 73
tumours, 67 (34 adenomas and 33 carcinomas) showed high
quality genomic profiles with MAD values ,0.2, giving an 8%
drop-out. In these 67 tumours, chromosome 20 gain occurred in
,15% of the adenomas but in .60% of the carcinomas (p
,0.001, as determined by CGHMultiArray), mostly affecting
either all of chromosome 20 or the q-arm only, similar to the
progressed adenomas (fig 1C,D; Supplementary fig 1B).
To determine the most relevant regions within 20q harbour-
ing putative oncogenes with a role in colorectal adenoma to
carcinoma progression, STAC32 was applied to the combined set
of paraffin-embedded malignant polyps (n = 41) and frozen
carcinomas (n = 33). This revealed three relevant regions of
aberrant copy gains on 20q, one spanning 4 Mb (32–36 Mb),
one spanning 3 Mb (56–59 Mb) and the third one spanning
2 Mb (61–64 Mb) (fig 2). These three regions (SROs) contained
80, 35 and 94 known genes, respectively.
Identification of differentially expressed genes
We performed microarray expression analysis on the 37 non-
progressed adenomas and 36 carcinomas for which snap-frozen
material was available. High quality expression array data were
obtained from 68 cases (37 adenomas and 31 carcinomas, 7%
drop-out).
Supervised data analysis for identifying putative oncogenes
on 20q was done in two different ways: we compared
carcinomas with adenomas, and we compared tumours with
20q gain with tumours without 20q gain. The first approach
revealed genome-wide 122 upregulated genes and 219 down-
regulated genes (a total of 341 differentially expressed genes) in
carcinomas when compared with adenomas (Wilcoxon test p
value ,1e-5 (FDR,0.05) and Thas p value ,0.05). Of these 122
upregulated genes, 14 map at chromosome 20q (table 1). For the
second approach, only tumours (adenomas and carcinomas)
that had both array CGH data and expression data available
(n = 64) were included. As a preselection, we used genes
Table 1 Genes significantly upregulated in carcinomas, when
compared with adenomas, mapping at 20q (Wilcoxon ranking p value
,1e-5 (ie, FDR,0.05) and Thas p value ,0.05), ordered by
chromosomal position (location in base pairs (bp) according to freeze
July 2003; NCBI Build 34) with HUGO gene symbols and GenBank
accession ID
Gene symbol
GenBank
accession no.
Location (bp
position)
Wilcoxon p
value
Thas p
value
C20orf1 (TPX2) NM_012112 31 103 374 2E-06 8E-05
MYRL2 NM_006097 35 859 501 5E-06 4E-05
C20orf24 (RIP5) NM_018840 35 923 014 2E-07 2E-05
TOMM34 NM_006809 44 265 329 8E-08 0
RBPSUHL NM_014276 44 626 010 2E-07 6E-06
BCAS4 NM_017843 50 138 063 2E-06 6E-05
AURKA (STK6) NM_003600 55 641 283 4E-10 0
FLJ37465 (BMP7) AK094784 56 477 906 1E-09 0
RNPC1 NM_017495 56 660 843 8E-07 7E-05
TH1L NM_016397 58 253 070 1E-06 1E-05
ADRM1 NM_007002 61 566 389 9E-07 8E-05
C20orf20 NM_018270 62 156 238 9E-09 0
TCFL5 NM_006602 62 211 152 2E-09 0
C20orf11 NM_017896 62 299 593 4E-07 0
FDR, false discovery rate.
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differentially expressed (both upregulated and downregulated)
between carcinomas and adenomas, as we focus on genes at 20q
that are involved in progression, using a less stringent cut-off
(Thas p value ,0.05). Thereby, we identified 127 genes genome-
wide out of 931 differentially expressed genes (regression
analysis; FDR (0.1) whose expression levels are influenced by
the occurrence of 20q gain. Of these 127 genes, 21 are mapped at
20q (table 2).
Nine genes common to these two approaches emerged,
namely TPX2, C20orf24, AURKA, RNPC1, TH1L, ADRM1,
C20orf20, TCFL5 and C20orf11.
Integration of array CGH and expression data
BAC array CGH data were related to oligonucleotide expression
array data, independently of adenoma or carcinoma status, using
a dedicated integration tool called ACEit.33 We obtained a list of
151 genes located at chromosome 20 for which gene dosage
affected expression levels (FDR (0.1), 120 of which are on the q-
arm (Supplementary table 2). Combining this information with
the results of the two supervised approaches for expression data
analysis (carcinoma vs adenoma and 20q gain vs no 20q gain),
seven genes were shared (fig 3). For these genes, C20orf24,
AURKA, RNPC1, TH1L, ADMR1, C20orf20 and TCFL5, combined
box plots with dot plots of mRNA expression in adenomas versus
carcinomas (fig 4A) and scatter plots of mRNA expression versus
DNA copy number ratio (fig 4B) are shown.
Of these seven candidate genes, six map within the SROs
determined by STAC analysis. The seventh gene (AURKA) maps
approximately 400 kb proximal to SRO2 at 55.6 Mb (20q13.31).
C20orf24 maps within SRO1 at 35.9 Mb (20q11.23), RNPC1 and
TH1L map within SRO2 at position 56.7 and 58.3 Mb,
respectively (20q13.32), and ADMR1, C20orf20 and TCFL5
map within SRO3, the first at 61.6 Mb and the other two at
62.2 Mb (20q13.33).
Stepwise linear discriminant analysis with leave one out cross-
validation showed that mRNA expression levels of two out of the
seven candidate genes—that is, RNPC1 and TCFL5—allowed
88.2% of the cases (60/68) to be correctly classified as adenomas or
carcinomas (fig 5 and table 3).
Confirmation of differential expression by qRT-PCR and
immunohistochemistry
qRT-PCR was performed on a subsample (n = 30) of frozen
tumours (15 adenomas and 15 carcinomas) to confirm the
expression levels of six of the seven genes identified.
Carcinomas showed higher expression of all six genes
compared with adenomas, and tumours with 20q gain (4
adenomas and 8 carcinomas) showed higher expression com-
pared with tumours without 20q gain (11 adenomas and 7
carcinomas). Table 4 shows the fold changes observed between
either carcinomas and adenomas or tumours with 20q gain vs
tumours without 20q gain, by microarrays and by qRT-PCR.
In situ confirmation of AURKA protein expression by
immunohistochemistry on TMAs yielded higher expression of
AURKA in carcinomas compared with adenomas (p = 0.01)
(table 5) as well as a significant positive correlation with the
mRNA expression levels (p = 0.01) (fig 6). Validation of other
genes was hampered by the absence of adequate antibodies.
DISCUSSION
One of the most frequent chromosomal aberrations observed in
CRC is gain of the long arm of chromosome 20. Nonetheless,
which of the many genes mapping at 20q show altered
expression due to DNA copy number alterations and play a
role in the progression of colorectal adenoma to carcinoma is
not yet fully understood. In order to try to identify these
putative oncogenes, we analysed a series of colorectal tumours,
both adenomas and carcinomas, at the DNA and RNA level.
In this study, we confirmed that chromosome 20 was the
most frequently altered in the progressed adenomas and
carcinomas (in .60% of cases). In non-progressed adenomas,
gains of 20q were detected in ,20%, supporting a role for 20q
gain in colorectal adenoma to carcinoma progression consistent
with earlier observations.7 Narrowing down the gained region
Figure 1 Frequency plot of DNA copy number gains and losses determined by bacterial artificial chromosome (BAC) array comparative genomic
hybridisation in (A) adenoma components of 41 progressed colorectal adenomas, (B) adenocarcinoma components of 41 progressed colorectal
adenomas, (C) 34 non-progressed colorectal adenomas and (D) 33 adenocarcinomas. The y-axis displays the fraction of tumours with either a gain
(positive sign) or loss (negative sign) for all clones that are sorted by chromosome and base pair position.
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by array CGH across all tumours analysed yielded three SROs:
SRO1 at 20q11.22–q11.23 (32–36 Mb), SRO2 at 20q13.32–
q13.33 (56–59 Mb) and SRO3 at 20q13.33 (61–64 Mb). Douglas
and collaborators,12 in a series of 48 cell lines and 37 primary
CRCs, defined 20q13.3 as the most common region of gain by
array CGH (at 62.3 Mb), which is included in SRO3. Moreover,
Nakao and collaborators,13 also by array CGH in a panel of 125
primary CRCs, observed like us more than one prominent
region of gain on 20q, centring at 32.3, 37.8, 45.4, 54.7, 59.4 and
65 Mb (according to the August 2001 freeze of the human
genome). Based on these array CGH data, the previous studies
listed several candidate oncogenes located at these genomic
regions, such as AIB4 (35 Mb), ZNF217 (53.9 Mb), CYP24
(54.5 Mb) and AURKA (56.6 Mb), and at 62.3 Mb the genes
LIVIN, PTK6, HD54 and EEF1A2. In the present study, the
defined regions SRO1, 2 and 3 harbour 80, 35 and 94 genes,
respectively, including AURKA, PTK6 and EEF1A2. Altogether,
based on copy number alterations alone, the number of genes is
still too high (209 genes, in total) really to pinpoint the genes
that play a role in the progression of colorectal adenoma to
carcinoma.
Comparison of the expression of carcinomas relative to
adenomas using strict statistical parameters showed that 14
genes mapping at 20q were overexpressed in carcinomas as
compared with adenomas. Most of these genes were not
described in previous expression microarray studies comparing
adenomas with carcinomas.36 37 These studies used either
Affymetrix arrays representing 6600 genes or cDNA microarrays
representing 23 000 genes as opposed to the 28 830 represented
on our oligonucleotides arrays. In addition, the number of
Figure 2 Delimitation of the smallest regions of overlap by STAC
(significance testing for aberrant copy number) analysis for 115 samples
(41 non-progressed adenomas, 41 adenocarcinoma components of
progressed adenomas, and 33 adenocarcinomas). Results for the long
arm of chromosome 20 are displayed. Rows represent samples, and
columns represent chromosomal locations. A black dot indicates a gain
called in a sample at a location. Consecutive black dots are connected by
a line to represent an interval of aberration. Grey bars track the maximum
STAC confidence (1 – p value); darker bars are those with confidence
.0.95. The line graph indicates the actual frequencies in the sample set.
Table 2 Genes whose expression is related to the 20q gain (FDR
(0.10), ordered by chromosomal position (location in base pairs (bp)
according to freeze July 2003; NCBI Build 34) with HUGO gene symbols
and GenBank accession ID
Gene symbol GenBank accession no. Location (bp position) FDR
HM13 NM_030789 30 874 805 0.03
C20orf1 (TPX2) NM_012112 31 103 374 0.03
CDC91L1 NM_080476 33 922 394 0.02
C20orf44 NM_018244 34 608 051 0.07
DLGAP4 NM_014902 35 761 669 0.05
TGIF2 NM_021809 35 897 616 0.003
C20orf24 (RIP5) NM_018840 35 923 014 0.0006
YWHAB NM_014052 44 210 177 0.0002
UBE2C NM_007019 45 128 792 0.01
DPM1 NM_003859 50 248 672 0.000001
NFATC2 AK025758 50 769 018 0.003
AURKA (STK6) NM_003600 55 641 283 0.02
RNPC1 NM_017495 56 660 843 0.04
TH1L NM_016397 58 253 070 0.007
ADRM1 NM_007002 61 566 389 0.05
SLCO4A1 NM_016354 62 015 102 0.08
C20orf20 NM_018270 62 156 238 0.04
TCFL5 NM_006602 62 211 152 0.03
C20orf11 NM_017896 62 299 593 0.0009
C20orf59 NM_022082 62 323 360 0.007
PRPF6 NM_012469 63 364 789 0.03
FDR, false discovery rate.
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Figure 3 Venn diagram integrating the results of three different data
analysis approaches (comparing colorectal adenocarcinomas vs
adenomas; colorectal tumours with 20q gain vs tumours without 20q
gain; and genome-wide integration of mRNA expression data with DNA
copy number data). Seven genes (C20orf24, AURKA, RNPC1, TH1L,
ADRM1, C20orf20 and TCFL5) emerge with all three approaches.
Figure 5 Scatter plot of mRNA expression levels of RNPC1
(NM_017495) and TCFL5 (NM_006602), by lesion (grey circles,
adenomas; black circles, carcinomas) showing a good separation of
colorectal adenomas vs carcinomas.
Colorectal neoplasia
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samples analysed in the present study is considerably higher,
with 4–10 times more adenomas and 2–3 times more
carcinomas. In combination with our multiangle, integrative
data analysis, the power of the present study thus is higher.
Two genes that have been described as being overexpressed in
colon tumours, compared with normal mucosa, are ADRM1 and
TOMM34.38 Moreover, cDNA expression analysis in a series of
clinical samples of CRC patients showed frequent upregulation
of TOMM34 in carcinomas, and inhibition of this gene by small
interfering RNA (siRNA) in the HCT116 colon cancer cell line
drastically reduced the cell growth.39 Together, these findings
corroborate our results since ADRM1 and TOMM34 are on the
list of genes that were shown to be upregulated in carcinomas
(compared with adenomas) (table 1). This lends support to the
approach of the present study, and suggests also that the other
candidates identified might be relevant.
Looking at the same expression data from a different angle—
that is, comparing the expression of tumours with and without
20q gain—we aimed to find genes with a dosage effect on
expression. Genome-wide, expression of 127 out of 931 genes
was related to 20q gain, 21 of which are located at chromosome
20q itself. Although chromosome 20 has a high gene density,
and copy number gains of the long arm are very frequent,
certainly not all genes mapping at the gained regions are
Figure 4 Integration of expression microarray data and array CGH (comparative genomic hybridisation) data of genes C20orf24, AURKA, RNPC1,
TH1L, ADRM1, C20orf20 and TCFL5. (A) Combined box plots with dot plots of mRNA expression (determined by oligonucleotide microarrays) in
colorectal adenomas and carcinomas. (B) Scatter plots showing correlation of mRNA expression (determined by oligonucleotide microarrays) and DNA
copy number (determined by bacterial artificial chromosome (BAC) array CGH).
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recurrently overexpressed. A total of 209 genes are mapped to
the SROs defined here, but only 21 genes are recurrently
upregulated in association with 20q gain, consistent with earlier
observations.40 41
Nine genes overlapped between the 14 adenoma versus
carcinoma genes and the 21 genes associated or not with 20q
gain, namely TPX2, C20orf24, AURKA, RNPC1, TH1L, ADRM1,
C20orf20, TCFL5 and C20orf11.
TPX2 and AURKA, differentially expressed between carcino-
mas and adenomas and associated with 20q gain, are known to
be related to aneuploidy and interact with each other.42
Moreover, in a microarray-based CIN gene signature, TPX2
ranked first.43 This finding supports the hypothesis that
chromosome 20q gain has an important role in colorectal
adenoma to carcinoma progression, and that the onset of
manifest CIN is instrumental.
Our third approach, integration of DNA copy number
changes and gene expression, demonstrated that throughout
the genome 507 genes showed a statistically significant
association between DNA copy number and mRNA expression
status, for both amplified/upregulated and deleted/down-
regulated genes, 120 of these being located on chromosome
20q. Some well-known genes, such as ZNF217 and CSE1L,
previously reported to be amplified in colon cancer,44–46 showed
relatively higher expression when there was allelic gain. From
these 120 genes, 17 overlapped with the 20q gain-associated
list, and 11 overlapped with the adenoma and carcinoma
versus carcinoma list. Overlapping these three approaches
(expression in adenomas vs carcinomas, expression with no
20q gain vs with 20q gain, and genome-wide expression vs
whole-genome copy number changes) showed that seven
genes are consistently significant (fig 3), namely C20orf24,
AURKA, RNPC1, TH1L, ADRM1, C20orf20 and TCFL5. In
addition to the already stringent data analysis, a permutation
analysis was performed, comparing the differential expression
of the seven 20q genes with the expression of .50 000 random
subsets out of 7946 genes in silent DNA regions (2q, 3, 5,10p,
11, 16, 21 and 22). For each random subset, the Wilcoxon
scores of the seven most differentially expressed (adenoma vs
carcinoma) genes were selected. The seven genes on 20q
showed a significantly higher expression in adenocarcinomas
versus adenomas compared with the best performing combi-
nation from the permutation test (p = 0.001), underlining that
the copy number-based discovery of putative oncogenes did
not yield random differentially expressed genes. The fact these
overexpressed putative oncogenes on 20q actually resulted in
biologically active components (ie, proteins) in the tumour
cells was demonstrated by immunohistochemistry on TMA
for AURKA. For the other candidates, antibodies did not
perform adequately in the tissue samples or were not available
at all.
Little is known about the function of most of these genes.
Some are transcription factors, like TCFL5,47 or otherwise
involved in transcriptional regulation, like C20orf20.48 The
product of TH1L is involved in regulation of A-Raf kinase.49
ADRM1 encodes a putative cell adhesion molecule that recently
was shown to be a component of the 26S proteosome.50 The
product of RNPC1 is predicted to bind to RNA, based on
Table 3 Results of stepwise linear discriminant analysis with leave one
out cross-validation of the seven candidate genes
Lesion
Predicted group membership
TotalAdenoma Carcinoma
Original
Count
Adenoma 35 2 37
Carcinoma 6 25 31
%
Adenoma 94.6 5.4 100.0
Carcinoma 19.4 80.6 100.0
From 68 tumours in total, 60 were correctly classified (88.2%), using expression levels
of RNPC1 and TCFL5 only.
Table 4 Expression fold changes and range of expression levels (log2 ratio) determined by expression microarray and by qRT-PCR, comparing either
carcinomas vs adenomas (Ca/Ad) or tumours with 20q gain vs tumours without 20q gain (20q gain/non-20q gain)
Gene Comparison
Microarray fold
change
qRT-PCR fold
change Microarray expression range* qRT-PCR expression range*
C20orf24 Ca/Ad 1.54 1.78 (20.45 to 1.60)/(20.71 to 0.71) (1.84 to 6.08)/(20.26 to 4.81)
20q gain/non-20q gain 1.68 3.99 (20.17 to 1.60)/(20.71 to 0.37) (20.26 to 6.08)/(1.85 to 4.95)
AURKA Ca/Ad 1.91 3.39 (22.01 to 0.17)/(22.26 to 21.11) (21.78 to 6.06)/(20.64 to 3.72)
20q gain/non-20q gain 1.55 4.53 (22.11 to 0.17)/(22.26 to 20.48) (1.03 to 6.06)/(21.78 to 3.99)
RNPC1 Ca/Ad 1.74 nd (21.61 to 1.22)/(21.80 to 20.41) nd
20q gain/non-20q gain 1.58 nd 21.71 to –1.22/21.80 to 20.01 nd
TH1L Ca/Ad 1.52 4.98 (20.77 to 1.39)/(21.06 to 20.15) (21.97 to 6.27)/(23.57 to 3.72)
20q gain/non-20q gain 1.59 6.4 (20.59 to 1.39)/(21. 06 to 0.10) (23.57 to 6.27)/(23.57 to 3.72)
ADRM1 Ca/Ad 1.45 1.46 (20.62 to 0.79)/(21.14 to 0.02) (20.30 to 5.58)/(21.29 to 5.34)
20q gain/non-20q gain 1.38 2.58 (20.69 to 0.78)/(21.14 to 0.36) (21.29 to 5.58)/(20.30 to 5.34)
C20orf20 Ca/Ad 1.36 3.08 (20.94 to 0.49)/(21.31 to 20.59) (21.32 to 2.07)/(22.79 to 0.14)
20q gain/non-20q gain 1.34 3.57 (20.89 to 0.49)/(21.31 to 20.36) (21.16 to 2.06)/(22.79 to 0.35)
TCFL5 Ca/Ad 2.2 3.54 (22.14 to 0.83)/(22.73 to 21.17) (2.07 to 6.94)/(21.28 to 4.21)
20q gain/non-20q gain 2.02 3.54 (22.31 to 0.83)/(22.73 to 20.93) (21.28 to 6.94)/(1.99 to 4.41)
*Log2 ratio.
nd, not determined; qRT-PCR, quantitative reverse transcription-PCR.
Table 5 AURKA protein expression in colorectal adenomas vs
carcinomas by immunohistochemistry on tissue microarray
AURKA staining
Total p Value*Negative Weak Strong
Lesion
Adenoma 12 12 1 25
Carcinoma 4 9 6 19
Total 16 21 7 44 0.01
*Cochran–Armitage test.
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sequence motifs, and C20orf24 interacts with Rab-5, although
its precise function is still unknown. AURKA has been well
characterized and is involved in cell cycle regulation. It has been
shown to be amplified in CRC51 and its overexpression induces
centrosome amplification, aneuploidy and transformation in
vitro.52 Moreover, inhibiting AURKA by RNA interference led to
Figure 6 (A) Examples of AURKA protein expression in tissue microarray cores of an adenoma showing no expression (0), an adenocarcinoma
showing weak expression (1) and an adenocarcinoma showing strong expression (2). (B) Combined box plot with dot plot of mRNA expression,
determined by oligonucleotide microarrays (y-axis), of colorectal adenomas and carcinomas with a negative (0), weak (1) or strong (2) protein
expression of AURKA on immunohistochemistry (x-axis).
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growth suppression of human pancreatic cancer cells.53
Knocking down TCFL5 resulted in suppression of the number
of multicellular HT29 tumour spheroids, supporting its role in
cancer development.54
In summary, we demonstrated the involvement of three
SROs in the 20q amplicon in CRC and showed strong DNA
copy number–mRNA expression associations for seven genes in
these areas. In addition we demonstrated significant differences
between colorectal adenomas and carcinomas at the DNA,
mRNA and, for one of the genes, the protein level, supporting
an important role as oncogenes in colorectal adenoma to
carcinoma progression. Furthermore, we showed that expres-
sion levels of two out of the seven genes allowed adenomas to
be discriminated from carcinomas with high accuracy. These
genes therefore may serve both as highly specific biomarkers for
CRC and as possible targets for pharmaceutical intervention in
the development of CRC.
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ANSWER
From the question on page 24
Colonoscopy revealed a localised area of mucosa inflammation
with a suspected fistulous tract opening at the colonic hepatic
flexure. Abdominal computed tomography (CT) and ultrasound
(US) showed the presence of a large gallstone occupying the entire
gallbladder and diffuse pneumobilia that raised the suspicion of a
biliary–enteric fistula. Subsequent endoscopic retrograde cholan-
giopancreatography showed an initial compression of the
common bile duct due to a large impacted gallstone, with
minimal dilatation of the intrahepatic ducts. It also showed a
cholecysto-colic fistula from which contrast entered the colon
delineating the right colonic haustration (fig 1A,B, below).
A diagnosis of large cholecysto-colic fistula was made with
associated Mirizzi syndrome type I.1 Biliary–enteric fistulas are
rare disorders usually developing insidiously and an association
with gallstones is always present. The most common type of
biliary–enteric fistula is cholecystoduodenal (75%); cholecysto-
colic is next common (15–20%) with a variety of other types (ie,
cholecystogastric) being less frequent (5–15%).2
Clinical manifestations of biliary–enteric fistulas are often not
specific including recurrent cholangitis, right upper quadrant pain,
jaundice, persistently abnormal liver biochemistry and, rarely,
gallstone ileus. It is remarkable that the predominant symptoms
in our patient were chronic diarrhoea and weight loss. The main
mechanism underlying these complaints is the malabsorption of
bile acids: since most of bile acids by-passed the small intestine
through the cholecysto-colonic fistula this resulted in a dimin-
ished fat absorption; in addition, the unusual high amount of bile
acids passing into the colon interfered with water absorption,
causing bile acid diarrhoea.
The patient underwent surgery and fistulectomy with
cholecystectomy (fig 2) and Roux-en-Y biliary–enteric anasto-
mosis resulted in prompt relief of symptoms.
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Figure 1 Cholangiograms showing
cholecysto-colic fistula and minimal
dilatation of intrahepatic ducts.
Figure 2 Large impacted stone in the gallbladder retrieved at surgery.
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